Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study.
Feliu J, Firvida JL, Castro J, Madroñal C, Rodríguez-Jaráiz A, Salgado M, Belda-Iniesta C, Casado E, García-Mata J, González-Barón M; Oncopaz Cooperative Group. Feliu J, et al. Cancer Chemother Pharmacol. 2009 Feb;63(3):403-9. doi: 10.1007/s00280-008-0749-z. Epub 2008 Apr 9. Cancer Chemother Pharmacol. 2009. PMID: 18398610 Clinical Trial.
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.
Ramírez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Tarón M, Ramírez de Molina V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, García-Cabezas MA, Sánchez JJ, Nistal M, Rosell R, González-Barón M, Lacal JC. Ramírez de Molina A, et al. Lancet Oncol. 2007 Oct;8(10):889-97. doi: 10.1016/S1470-2045(07)70279-6. Lancet Oncol. 2007. PMID: 17851129
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M, Chattopadhyay S, Rovira A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, Cejas P, Machado-Pinilla R, Manguan-García C, Sánchez-Pérez I, Nistal M, Moratilla C, de Castro-Carpeño J, Gonzalez-Barón M, Albanell J, Perona R. Cortes-Sempere M, et al. Cancer Lett. 2009 Dec 28;286(2):206-16. doi: 10.1016/j.canlet.2009.05.029. Epub 2009 Jun 23. Cancer Lett. 2009. PMID: 19553005
PI3K/Akt signalling pathway and cancer.
Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. Fresno Vara JA, et al. Cancer Treat Rev. 2004 Apr;30(2):193-204. doi: 10.1016/j.ctrv.2003.07.007. Cancer Treat Rev. 2004. PMID: 15023437 Review.
Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells.
Belda-Iniesta C, Perona R, Carpeño Jde C, Cejas P, Casado E, Manguan-García C, Ibanez de Caceres I, Sanchez-Perez I, Andreu FB, Ferreira JA, Aguilera A, de la Peña J, Perez-Sánchez E, Madero R, Feliu J, Sereno M, González-Barón M. Belda-Iniesta C, et al. Cancer Biol Ther. 2007 Oct;6(10):1600-5. doi: 10.4161/cbt.6.10.4726. Epub 2007 Jul 12. Cancer Biol Ther. 2007. PMID: 17938574
Molecular biology of pancreatic cancer.
Belda-Iniesta C, Ibáñez de Cáceres I, Barriuso J, de Castro Carpeño J, González Barón M, Feliú J. Belda-Iniesta C, et al. Clin Transl Oncol. 2008 Sep;10(9):530-7. doi: 10.1007/s12094-008-0247-6. Clin Transl Oncol. 2008. PMID: 18796369 Review.
225 results